

第2回 国際エキスパートセミナー

PD-L1 immunohistochemistry is the best predictive biomarker for PD-1/PD-L1 blockade? - an experience with NSCLC

2018年11月27日 TUE 17:00～

場 所

金沢大学附属病院 外来診療棟4階
CPDセンター

講 師

ハーバード大学 医学部病理学 教授
Dr Mari Mino-Kenudson

座 長

金沢大学 人体病理学 教授
原田 憲一

PD-L1 expression by immunohistochemistry (IHC) is used to select lung cancer patients for PD-1/PD-L1 axis blockade. However, there are multiple issues associated with PD-L1 IHC. Importantly, PD-L1 expression only may not be the best predictor of response to the blockade. In this talk, I will discuss the issues associated with PD-L1 IHC, and other potential biomarkers to improve the prediction of response to the PD-1/PD-L1 blockade.

profile

Dr. Mino-Kenudson is Professor of Pathology at Harvard Medical School and the director of Pulmonary Pathology service at Massachusetts General Hospital, Boston, USA. She has been conducting translational research on lung cancer in collaboration with molecular pathologists, thoracic oncologists, and basic scientists. She and her team have described the morphology of molecularly annotated and/or biologically aggressive lung adenocarcinomas. They were the first group to report the signet ring cell morphology associated with *ALK* rearranged lung adenocarcinomas, as well as tumor islands, which associate with *KRAS* mutations and unfavorable patient outcomes, and are now considered to represent airspace invasion. They also documented the utility of clinical testing to identify molecularly defined lung adenocarcinomas. The *ALK* and *ROS1* FISH as well as *ALK* immunohistochemistry (the clone D5F3) that they reported have significantly facilitated the detection of patients with actionable gene arrangements (game-changing innovations). She and her collaborators have also been actively investigating resistant mechanisms for EGFR, *ALK* and *ROS1* tyrosine kinase inhibitors that will aid in identifying appropriate treatment for those patients after development of resistance to the inhibitors. She has contributed to the 2015 WHO classification of lung tumours and is a member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).



主 催

北信がんプロ(超少子高齢化地域での先進的がん医療人養成)

お問い合わせ

金沢大学 北信がんプロ事務局

TEL

076-234-4205

E-mail

gpro@med.kanazawa-u.ac.jp

URL

<http://www.gan-pro.net/>